Managing high homocysteine levels during levodopa treatment
Researchers investigate treatment to lower raised blood homocysteine, a substance made by the body, in people with Parkinson’s taking levodopa.
Testing a treatment or activity · Study reference: NCT06772220
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (reported actual date)
- 2024-03-05
- Main measurements finished (planned)
- 2025-12-31
- Study finished (planned)
- 2025-12-31
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
- 2026-10-11 — recruiting
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Ages 40 years to 90 years · Does not accept healthy volunteers
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: all
Full study name & original research details
Official study title
Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease
Original description
Conditions reported: Parkinson&Amp;#39;s Disease
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- ClinicalTrials.gov · NCT06772220 ↗ — RECRUITING; checked 2026-10-13
- ClinicalTrials.gov · NCT06772220 ↗ — Recruiting; WHO ICTRP processed 2025-01-27; checked 2026-10-13
- Study type
- Interventional
- Interventions
- Folic Acid 1 MG; Vitamin B6 25 MG; Vitamin B12
- Phases
- NA
- Sponsor
- Oregon Health and Science University
- Start date reported by registry
- 2024-03-05 (actual)
Registry updated: 2025-01-13 · Status last verified by the registry submitter: 2025-01
Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
Madeline Armendariz Sullivan · 503-501-8478 · PDResearch@ohsu.edu
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
RecruitingMadeline Armendariz Sullivan · 503-501-8478 · PDResearch@ohsu.edu
Facility not reported
United States
Status not reportedThe original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.